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Purpose: To prepare, using non-solvent addition technique, diclofenac sodium-ethylcellulose 
microparticles with modified drug release properties. 
Methods: Microparticles were prepared by non-solvent addition phase separation method and 
characterized by micromeritics, scanning electron microscopy (SEM), Fourier transform infrared 
spectroscopy (FTIR), x-ray diffraction (XRD), dissolution test and thermal analysis. 
Results: The microparticles were whitish, irregular, aggregated, and in the size range of 390 - 442 µm 
size. Drug embedment efficiency was 89 - 91 %. Characterisation studies indicate that there was no 
strong chemical interaction between the drug and the polymer in the microparticles. Polymer 
concentration and sustained release behavior were directly proportional. 
Conclusion: Non-solvent addition phase separation is a suitable method for preparing diclofenac 
sodium-ethylcellulose multi-unit controlled release drug delivery system. 
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INTRODUCTION 
 
Chronic diseases require drugs with 
extended therapeutic effect and this can be 
achieved either by the development of drugs 
with long half-life or sustained release drug 
delivery systems. Several approaches have 
been employed to prepare systems for the 
sustained delivery of drug. 
Microencapsulation is one of the techniques 
that has been used to develop multi-unit 
sustained release dosage forms which are 
regarded as more reliable for the uniform 
distribution of drug in the gastrointestinal tract 
[1]. 
 
Diclofenac sodium (DS), a phenylacetic acid 
derivative, is an NSAID with a pKa of 4.0. It 
exists in acidic form in acidic solutions such 
as gastric juice, and is practically insoluble in 
water but soluble in intestinal fluid [2]. It is 
rapidly absorbed when given orally and is 
used for the management of pain and 
inflammation in various musculoskeletal and 
joint disorders. Its plasma half-life is about 1 - 
2 h and its usual oral dose is 75 to 150 mg 
daily in divided doses [3]. On the basis of the 
pharmacokinetic properties of diclofenac 
sodium, it is a suitable candidate for 
microencapsulation. 
 
Ethylcellulose (EC) with complete ethoxyl 
substitution (DS = 3) is C12H23O6(C12H22O5)n 
C12H23O6 where “n” can vary to provide a 
wide variety of molecular weights. 
Ethylcellulose, an ethyl ether of cellulose, is a 
long chain polymer of β-anhydroglucose units 
joined together by acetal linkages. It is 
generally considered a non-toxic, biocom-
patible and non-biodegradable polymer. 
These characteristics are the reasons for its 
extensive use in the development of oral 
dosage forms, especially sustained release 
formulations, including oral multi-unit dosage 
forms (i.e., microparticles) [4]. 
 
The literature contains some citations on 
microencapsulation of diclofenac sodium 
using various techniques [5,6]. None of 
these, to the best of our knowledge, 
described the characterisation of the 
microparticles by micromeritics, scanning 
electron microscope, FTIR, thermal analysis 
and X-ray diffractometry. Furthermore, no 
record was found of the microencapsulation 
of diclofenac sodium with non-solvent 
addition phase separation method. 
Consequently, and in view of the 
pharmacokinetic profile of DS, the objective 
of this study was to prepare and evaluate DS 






Diclofenac sodium (DS) was donated by 
Sami Pharmaceuticals, Pakistan. Ethyl 
cellulose (22 cp, EC) was purchased from 
Sigma, USA. All other chemicals (analytical 
grade) were purchased from various 
commercial sources.  
 
Preparation of microparticles 
 
EC (1 g) was dissolved in 20 ml of toluene 
containing polyisobutylene (6 %w/w) in a 
closed beaker with magnetic stirring (Velp, 
Europe) at 500 rpm for 6 h, followed by 
dispersion of DS in it. After stirring the system 
for 15 min, phase separation was induced by 
adding petroleum benzin (non-solvent). The 
product was transferred to an ice bath to 
solidify the microparticles. The microparticles 
were treated with chilled petroleum benzin 
five times while still stirring, washed with n-
hexane and dried in air for 2 h followed by 
drying in an oven (Memmert, Germany) at 50 
°C for 4 h. Three batches of microparticles, 
viz, M1, M2 and M3, were prepared with 
drug:polymer ratio of 1:1, 1:2 and 1:3, 
respectively. 
 
Embedment efficiency  
 
A quantity (50 mg) of the microparticles was 
added to methanol (15 ml) and sonicated for 
3 min to remove EC. Sufficient amount of 
water (50 ml) was added, the system heated 
to evaporate methanol and then filtered. After 
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suitable dilution, the resultant solution was 
analysed spectrophotometrically at 276 nm 
(predetermined maxima for DS) using a UV-
Vis spectrophotometer (model 1601, 
Shimadzu, Japan). The concentration of DS 
was obtained from the calibration curve
5 
and 
DS loading (%) and embedment efficiency 
(%) were calculated using the Eqs 1 and 2, 
respectively. 
 
Drug loading (%) =  W1/W × 100…………...….. (1) 
 
where W1 is among of drug in microcapsules 
and W is weight of microcepsules 
 
Embedment efficiency (%) =  La/L × 100 ..…. (2) 
 
where La is the actual drug loading and L is 
the theoretical drug loading 
  
Yield efficiency  
 
The yield (%) of microparticles was 
calculated as shown in Eq 3.  
 
Production yield (%) =  × 100  ………… (3) 
 
where, M and Mt are the weights of 
microparticles and starting materials (Mt, total 
weight of DS plus EC), respectively[7,8]. 
 
Microparticle size  
 
The mean diameter of the microparticles was 
determined using a light microscope 
equipped with a microscope stage and a 
digital camera connected to a computer. The 
microparticles were suspended in water, 
placed on a glass slide, and observed 
through the microscope. Photomicrographs 
were taken with the camera and the 
microparticle diameter determined by image 
analysis. 
 
Scanning electron microscopy (SEM) 
 
The morphology of the microparticles was 
examined by scanning electron microscopy 
(SEM, Shimadzu, Japan) after coating with 
palladium [9]. 
Fourier Transform Infrared Spectroscopy 
(FTIR) 
 
DS, EC and DS-EC microparticles were 
studied by Fourier Transform Infrared (FTIR) 
spectroscopy (MIDAC M2000, USA) after first 
incorporating them in KBr disc in order to 
study DS-EC interaction.  
 
X-ray diffractometry   
 
X-ray diffractometry of DS, EC and DS-EC 
microparticles was conducted to evaluate the 
effect of microencapsulation technique on the 
crystallinity of DS using D8 Discover (Bruker, 
Germany). The samples were scanned in the 
8 to 70° diffraction angle range under the 
following conditions: Cu-K∞ radiation 1.5406 
A° (source), 4°/min scan speed, scintillation 
detector, primary slit 1 mm, secondary slit 0.6 
mm. 
 
Thermal analysis  
 
Differential scanning calorimetry (DSC), 
thermogravimetric analysis (TGA) and 
differential thermometric analysis (DTA) (TA 
Instruments, USA) of 10 mg powdered 
samples of DS-EC microparticles as well as 
DS and EC were carried out to determine 
DS-EC interaction. The samples were placed 
in an alumina pan at a heating rate of 10 
°C/min under a nitrogen flow of 40 ml/min. 
 
Micromeritic properties  
 
Micromeritic properties of microparticles were 
also studied. Bulk and tapped densities were 
assessed by the conventional tapping 
method (see Eqs 4 and 5) using a 10 ml 
graduated measuring cylinder as a measure 
of packability of microparticles.  
 
Bulk density = W/V .……………….……... (4) 
 
where W and V are the weight  and volume, 
respectively. 
 
Tapped density = Wt/Vt ……………….…. (5) 
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where Wt and Vt are the weight and volume 
of particles, respectively, after 100 tappings   
 
Compressibility index (Ci) and Hausnner’s 
ratio were also determined as indices of 
microparticles flowability as in Eqs 6 and 7, 
respectively.  
 
Ci = {(Vo – Vf)/Vo}   x 100 ……………….. (6) 
 Where Vo and Vf are the initial and finaly 
volume of the particles, respectively. 
 
Hausnner’s ratio = V/Vt ………………….... (7) 
 
where V and Vt are the volume before and 
after tapping respectively 
 
Angle of repose (θ) of microparticles was 
measured using the fixed-base cone method 
and calculated as in Eq 8 [5,10]. 
 
θ = tan -1.h/r …………………….………….. (8) 
 
where r is the radius of cone base and h is 
the height of the cone. 
 
Stability studies  
 
Microparticles (500 mg) were sealed in an 
air-tight amber colour glass vial and stored at 
20°C/60% RH, 30°C/65% RH and 40°C/75% 
RH. The microparticles were evaluated for 
drug content and release profile 
spectrophotometrically (as described above) 
weekly for eight weeks. One vial was used in 
each evaluation. 
 
In vitro dissolution studies  
 
In vitro drug release evaluation of accurately 
weighed DS microparticles, containing 100 
mg DS, was carried out in 900 ml of double 
distilled water maintained at 37 ± 0.7 °C and 
stirred at 50 rpm, using a USP XXIV Type II 
dissolution test apparatus (Pharmatest, 
Germany). Aliquots (5 ml) were withdrawn 
and filtered automatically at various time 
intervals, replenishing the medium with 5 ml 
of dissolution medium after each withdrawal. 
The samples were analysed spectrophoto-
metrically at 276 nm. The concentration of 
DS was obtained from the calibration curve 
generated [11, 5]. 
 
Assessment of release mechanism 
 
In the model-dependent approach, various 
kinetic models were applied to the release 
profiles, as in Eqs 9 – 13.  
 
Zero order [12]: Mt = Mo+ Kot  ……….....  (9)  
First order [12]: ln Mt = ln Mo + K1t  ……  (10)  
Higuch[13]i:     Mt = Mo + KHt
1/2
   ……….  (11)  
Hixson-Crowell [14]: Mo
3
 - Mt 
3
= KHCt ....    (12)  
Korsmeyer-Peppas [15]: Mt/Mα = Kkt
n
….   (13)  
 
where, Mt is the cumulative amount of drug 
released at any specified time point and Mo is 
the initial amount of drug in the formulation. 
Ko, K1, KH, KHC and Kk are rate constants for 
zero order, first order, Higuchi, Hixson-
Crowell and Korsmeyer-Peppas models, 
respectively. In Eq 13, Mt/Mα is the 
percentage of TH released at time t and n is 
the release exponent that characterises 
different release mechanisms.  
 
In the model-independent approaches, 
ANOVA-based and pair-wise procedures 
were applied to the release data. One way 
ANOVA plus Post-Hoc analysis (Duncan and 
Tukey H.S.D.) for significance at P < 0.05 
was conducted for whole release profiles 
using SPSS version 12.0.[16] Pair-wise 
procedures include the difference factor (f1), 
as shown in Eq 14, and the similarity factor 
(f2) as indicated in Eq 15. According to FDA 
guidelines, values of f1 between 0 and 15 and 
of f2 between 50 and 100 ensure sameness 
or equivalence of the two dissolution profiles. 
In both equations, Rt and Tt represent 
dissolution measurements at P time points of 









Rt]}   ……….  (14) 








 *100} ...  (15) 
 
Estimation of swelling and erosion of 
microparticles 
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The microparticles were also evaluated for 
their swelling and erosion behavior to 






formulation (100 mg) was placed in 900 ml of 
double distilled water for 12 h and then 
weighed again after blotting out excess fluid 
on the surface of microparticles. It was dried 
at 40 °C for 48 h and then weighed. Swelling 
(%) and erosion (%) were determined using 
Eqs 16 and 17, respectively. 
 
Swelling (%) = S/R × 100   …………....   (16) 
 
Erosion (%) = (T - R)/T × 100   ……….   (17) 
 
where T is the initial weight of the 
microparticles; S is the weight of the 
microparticle matrix after swelling; and R is 




Embedment efficiency and Microparticle 
size 
 
Microparticle drug embedment efficiency 
increased as drug:polymer ratio was varied 
from 1:1 to 1:2 to 1:3. Microparticles prepared 
with drug:polymer ratio of 1:3 showed 
optimum drug embedment (88.9, 90.0 and 
90.9 % for M1, M2 and M3, respectively). No 
significant change (p < 0.05) in drug 
embedment efficiency was observed with 
further increases in EC concentration, as 




Good yield efficiency (~ 90 %) was achieved 
for all batches. Increased polymer 
concentration did not increase yield 
significantly (p < 0.05) (see Table 1) [5]. 
 
Scanning electron microscopy 
 
From the SEM results, the microparticles 
were irregular in shape with deep cracks on 




Figure 1: Scanning electron micrographs of 
diclofenac sodium microparticles with 
drug:polymer ration of 1:2 (M2) 
 
Fourier transform infrared spectroscopy 
 
FTIR spectra in Figure 2 showed no 
degradation of drug during 
microencapsulation. Amino peak (N-H 
stretching) and C-Cl stretching appeared at 
3320 and 768, respectively, representing DS 
in EC. Aromatic peak (C-H stretching) at 
3020 confirmed the presence of EC. The 
nature of the peaks did not vary for pure drug 
or polymer and microparticles, indicating that 
there was no interaction between the drug 




X-ray powder diffraction patterns of DS 
revealed its crystalline form. DS crystallinity 
decreased following its incorporation in the 
microparticles as indicated by the 




The results of the thermal analysis 
evaluations are shown in Figure 3. They 
show that the thermograms of the pure drug 
and M2 exhibited identical peaks 
(endotherms) at about 75 °C, indicating that 
the drug was largely intact in the 
microparticles. This finding is essentially 
supported by the DTA thermograms. 
However, the slope is slightly more curved in 
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the M2 endotherm, probably due the loss of 
drug crystallinity during microencapsulation 
as explained in the section on x-ray 
diffraction.  
 
The DSC thermograms for for DS alone and 
DS-EC show an endothermic peak at 70 °C 
but with reduced peak sharpness for the 
latter, indicating slight variation in the 




Figure 2: FTIR spectra and x-ray diffractograms of 
diclofenac sodium (DS), ethyl cellulose (EC) and 




Micromeritic data for the microparticles are 
listed in Table 1. Pure DS and the 
microparticles showed almost identical bulk 
and tapped densities. However, angle of 
repose and compressibility data indicate that 
the microparticles exhibited better flow 




Figure 3: Thermograms of diclofenac sodium 
(DS), ethyl cellulose (EC) and microparticles with 
drug:polymer ratio of 1:2 (M2). 
 
In vitro dissolution studies 
 
Figure 4 shows the in vitro release results for 
DS and microparticle formulations. Polymer 
concentration influenced drug release from 
the microparticles. Sixty percent drug release 
from pure DS, M1, M2 and M3 was achieved in 
0.12, 1.70, 2.06 and 2.33 h, respectively, thus 
indicating that the microparticle formulations 
resulted in sustained release of the drug. 
 
Swelling and erosion of microparticles  
 
Formulation M2 undergoes swelling (101 to 
138 %) and erosion (2.47 to 6.28%)  
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Table 1: Physicochemical and rheological properties of diclofenac sodium microparticles 
 
  Pure diclofenac 
sodium 
M1 M2 M3 
1 Drug: Polymer ratio - 1:1 1:2 1:3 
2 Embedment efficiency (%) - 88.94 90.04 90.89 
3 Yield efficiency (Mean ± 
SD) % 
- 
89.87±1.29 90.57±1.15 90.23±1.24 
4 Size (Mean Diameter) 
(Mean ± SD) µm 
- 
389.62±14.15 410.94±09.64 442.19±18.15 
5 t 60% (Mean ± SD) (h) .12 1.70 2.06 2.33 
Rheological properties of diclofenac sodium and its microparticles  
6 Bulk density (g/ml) 0.25 0.30 0.24 0.28 
7 Taped density (g/ml) 0.22 0.24 0.29 0.27 
8 Compressibility index (%) 9.72 12.43 11.09 12.93 
9 Hausner’s ratio 1.03 1.22 1.15 1.19 






























Figure 4: The dissolution profiles of diclofenac 
sodium microparticles showing the effect of 
polymer concentration. Each data point is a mean 
of three values. (-♦- = Pure diclofenac sodium; -□- 
= M1; -∆- = M2; -×- = M3)   
 
continuously with time (0 to 12 h) after putting 




No significant variation in the drug contents of 
the microparticles stored in 20 °C/60% RH, 
30°C/65% RH and 40 °C/75% RH, was 
observed for eight weeks. Drug embedment 
efficiency and the release profiles did not 
vary during this period. Thus DS-EC 
microparticles showed good stability in these 
conditions. After 8 week storage, the drug 
contents of microparticles stored at 25 
°C/60% RH, 30 °C/65% RH and 40 °C/75% 




The results indicate that embedment 
efficiency varied with microparticle size. 
Large size microparticles had higher 
embedment efficiency. This may be due to 
increase in system viscosity with increase in 
EC concentration. Increased viscosity would 
cause adherence of a higher number of 
individual particles, thus resulting in larger 
microparticles. These results are, therefore, 
comparable with previous findings which also 
certify that there is an increase in embedment 
efficiency and particle size with the increase 
in EC concentration 
5,6
. Magnetic stirring 
speed and its duration did not affect 
embedment efficiency. However, prolonged 
stirring at higher speed produced 
microparticles with low size.  
 
The virtual lack of change in the thermal 
behavior and FTIR spectra of DS after 
inclusion in the microparticles indicates 
probable absence of drug-polymer 
interaction. This finding therefore, indicates 
good stability of DS in DS-EC microparticles. 
Furthermore, formulation of the drug in 
microparticle form improved its packability 
and flow characteristics, which in turn should 
facilitate handling. 
 
Microparticles with low polymer concentration 
released drug quickly probably because they 
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were smaller in size and, therefore, provided 
a larger surface area for drug release based 
on the modified Noyes-Whitney equation18 
shown in Eq 18 
(dc/dt) = kS (Cs – Ct)  ………………….   (18) 
 
where dc/dt is the rate of dissolution, k is the 
dissolution rate constant, S is the surface 
area of the dissolving body and Cs – Ct is the 
concentration gradient. 
 
Drug release from the microparticles were 
also evaluated by mathematical kinetic 
models. From Duncan test, t60% of all 
microparticle batches was in the same 
homogenous group (M1=M2=M3) whereas 
Tukey H.S.D. similarized t60% of M1 and M2, 
and differentiated them from that of M3 but 
not significantly (p > 0.05). Based on the 
difference factor (f1) and similarity factor (f2), 
the release profiles of the following 
microparticle formulations were different from 
each other: M1 vs M3 with f1 > 15.0 and f2 < 
50.0, while M1 vs M2 and M2 vs M3 have f1 < 
15.0 and f2 > 50.0 which indicates the mutual 
similarity of the compared release profiles but 
to a much less extent. With a decreasing core 
to wall ratio, the velocity of drug release 
would decreases since it can be assumed 
that with decreasing core to wall ratios, wall 
thickness of microparticles increases which 
then slows down the diffusion of the 
dissolution medium into the microparticles. 
This is because the number of surface pores 
would decrease with increasing polymer 
concentration [9,19]. 
 
The Higuchi model best explained the drug 
release pattern, i.e., release of drug is directly 
proportional to the square root of time with R
2
 
value of 0.973. Anomalous diffusion was the 
mechanism of drug release from 
microparticles. Subjection of the release data 
to the Hixson-Crowell equation indicated a 
change in surface area and diameter of the 
formulations with progressive dissolution of 
the matrix as a function of time. The slight 
swelling and moderate erosion of the 
microparticles is likely to be responsible for 
the slow release of drug from the matrix of 
the micropparticles. It also supports 





This study demonstrates that non-solvent 
addition phase separation is a useful 
technique for the microencapsulation of 
diclofenac sodium with ethylcellulose for 
sustained release. Characterization studies 
indicate that interaction of the components of 
the microparticles was physical, and that 
there was no chemical interaction between 
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